The TaMADOR consortium has launched a new website at tamador.org. TaMADOR — Targeted Mass Spectrometry Assays for Diabetes and Obesity Research — brings together research groups funded by two NIDDK programs to develop and disseminate targeted mass spectrometry assays for the diagnosis and monitoring of Type 1 Diabetes and Obesity.

The consortium includes four participating institutions:

  • University of Washington (PIs: Andrew Hoofnagle, Michael MacCoss) — Quantifying proteins in plasma to democratize personalized medicine for patients with Type 1 Diabetes
  • PNNL & University at Buffalo (PIs: Jun Qu, Wei-Jun Qian) — Robust mass spectrometric protein/peptide assays for Type 1 Diabetes clinical applications
  • Cedars-Sinai Medical Center (PI: Jennifer Van Eyk) — Design and validation of easy-to-adopt mass spectrometry assays of importance to Obesity
  • Pacific Northwest National Laboratory (PI: Wei-Jun Qian) — Multiplex mass spectrometric protein assays for precise monitoring of the pathophysiology of Obesity

The site features publications, datasets, meeting information, and links to the Panorama data repository. Check it out at https://tamador.org.